2020
Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical Cancer Research 2020, 26: 3928-3935. PMID: 32601075, PMCID: PMC8792803, DOI: 10.1158/1078-0432.ccr-20-0953.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemotherapy, AdjuvantCystadenocarcinoma, SerousCytoreduction Surgical ProceduresDrug Administration ScheduleEndometrial NeoplasmsEndometriumFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPaclitaxelProgression-Free SurvivalReceptor, ErbB-2Survival AnalysisTrastuzumabConceptsProgression-free survivalRandomized phase II trialPhase II trialOverall survivalHER2/neuStage IIICarboplatin-paclitaxelII trialRecurrent diseaseControl armSurvival analysisRecurrent uterine serous carcinomaCarboplatin/paclitaxelUterine serous carcinomaOverall survival analysisEvaluable patientsEligible patientsPrimary endpointSecondary endpointsEndometrial cancerAggressive variantSerous carcinomaPrimary treatmentSurvival medianPatients
2016
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Molecular Cancer Therapeutics 2016, 15: 1900-1909. PMID: 27256376, DOI: 10.1158/1535-7163.mct-16-0163.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsAntibody-Dependent Cell CytotoxicityAntineoplastic AgentsBystander EffectCathepsin BCell Line, TumorCell SurvivalClass I Phosphatidylinositol 3-KinasesCystadenocarcinoma, SerousDisease Models, AnimalDuocarmycinsFemaleGene ExpressionHumansImmunoconjugatesIndolesMiceMiddle AgedMutationPhosphatidylinositol 3-KinasesPyrrolidinonesReceptor, ErbB-2Survival AnalysisUterine NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous carcinomaAntibody-dependent cellular cytotoxicityHER2/neu expressionAntibody-drug conjugatesT-DM1Neu expressionHER2-targeting antibody-drug conjugateNovel antibody-drug conjugateNovel HER2-targeting antibody-drug conjugatePrimary USC cell linesHigh HER2 expressionHER2/neu oncogeneHER2/neuMouse xenograft modelUSC cell linesFlow cytometry assayEndometrial cancerSerous carcinomaHER2 expressionTrastuzumab emtansineClinical studiesCellular cytotoxicitySYD985Aggressive formExpress HER2
2014
Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract
Ahmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, Xu ML, Schwartz PE, Ratner E. Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract. International Journal Of Gynecological Cancer 2014, 24: 1250-1255. PMID: 25010039, PMCID: PMC8139417, DOI: 10.1097/igc.0000000000000201.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDiagnosis, DifferentialDoxorubicinFemaleGenital Neoplasms, FemaleGynecologic Surgical ProceduresHumansLymphoma, Non-HodgkinMiddle AgedPrednisolonePrednisonePregnancyPregnancy Complications, NeoplasticRetrospective StudiesSurvival AnalysisTeniposideVincristineYoung AdultConceptsNon-Hodgkin lymphomaFemale genital tractGenital tractGynecologic malignanciesPara-aortic lymph nodesPrimary non-Hodgkin lymphomaDiffuse large B-cell lymphomaYale-New Haven HospitalLarge B-cell lymphomaConcomitant radiation therapyRadical gynecologic surgeryCommon histologic typeOverall median survivalSingle institution experienceStem cell transplantationRare gynecologic malignancyDiagnosis of lymphomaAnn Arbor systemB-cell lymphomaWorld Health OrganizationMedian survivalRecurrent diseaseCombination chemotherapyMedian ageUterine corpus
2012
Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV)
Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi D, Santin AD, Schwartz PE. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal Of Surgical Oncology 2012, 107: 195-200. PMID: 22648987, DOI: 10.1002/jso.23171.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Ovarian EpithelialChemotherapy, AdjuvantCohort StudiesDrug Administration ScheduleFemaleHumansNeoadjuvant TherapyNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsEpithelial ovarian cancerAdvanced stage ovarian cancerUpfront cytoreductive surgeryNeoadjuvant chemotherapyStage ovarian cancerCytoreductive surgeryOvarian cancerNACT patientsAge 70Stage IV epithelial ovarian cancerAdvanced epithelial ovarian cancerImproved progression-free survivalRetrospective cohort studyShorter ICU stayStage IV diseaseProgression-free survivalLess blood lossSmall bowel resectionOverall survival analysisICU staySame chemotherapyUpfront surgeryMacroscopic diseasePerioperative morbidityStage IIIC
2009
Ovarian preservation and staging in reproductive-age endometrial cancer patients
Richter CE, Qian B, Martel M, Yu H, Azodi M, Rutherford TJ, Schwartz PE. Ovarian preservation and staging in reproductive-age endometrial cancer patients. Gynecologic Oncology 2009, 114: 99-104. PMID: 19410280, DOI: 10.1016/j.ygyno.2009.03.032.Peer-Reviewed Original ResearchConceptsDisease-free survivalLonger disease-free survivalYale-New Haven HospitalEndometrial cancer patientsOvarian preservationSurgical stagingOverall survivalEndometrial cancerCancer patientsEarly-stage low-grade endometrial cancerStage IYoung endometrial cancer patientsBetter disease-free survivalLow-grade endometrial cancerGrade 1 diseaseRetrospective chart reviewLonger overall survivalChart reviewYounger patientsClinical stagingSurgical treatmentEndometrial carcinomaGynecologic pathologistsRisk factorsAge 45